Trinity Biotech plc TRIB
At closeNov 10, 2026, 4:00 PM EST
After hours · Nov 10, 4:00 PM ET
- YTD
- -75.19%
- 1 year
- -79.15%
- Market cap
- 4.78M
- Revenue (ttm)
- 58.65M
- Profit margin
- -38.01%
- EPS (ttm)
- -60.00
- Shares out
- 27.52M
- Forward P/E
- -0.87
- YTD return
- -75.19%
- 1-year return
- -79.15%
- Volume
- 7.05K
- Avg volume
- 18.92K
- Open
- 5.59
- Previous close
- 5.34
- Day's range
- 5.37 – 5.94
- 52-week range
- 5.00 – 52.50
- Beta
- 1.13
5D -1.44 (-21.24%)
Key statistics
- Enterprise value
- 347.37M
- PEG ratio
- 0.00
- Price / sales
- 0.42
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 14.00%
- Free cash flow
- -9.93M
- Total cash
- 5.32M
- Total debt
- 93.33M
- Return on equity
- 0.00%
- Short % of float
- 2.43%
- 50-day average
- 1.39
- 200-day average
- 1.90
Next earnings
Consensus EPS estimate -0.30.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 15, 2024 | Sep 1, 2024 | -0.54 | -0.43 | +0.11 | +20.37% |
| Aug 14, 2024 | Jun 1, 2024 | -0.65 | -0.55 | +0.10 | +15.38% |
| May 23, 2024 | Mar 1, 2024 | 0.00 | -0.37 | — | — |
| Apr 4, 2024 | Dec 1, 2023 | 0.00 | -0.68 | — | — |
| Oct 3, 2023 | Jun 1, 2023 | 0.00 | -1.00 | — | — |
| Jul 6, 2023 | Mar 1, 2023 | 0.00 | -0.80 | — | — |
About Trinity Biotech plc
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders. The company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- Ireland
- Website
- trinitybiotech.com
News
Your note
Sign in to keep a note on TRIB — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perceptive Advisors Llc | 79.72% | 1,800,000 | 1.61M | Sep 29, 2024 |
| Hunter Associates Investment Management LLC | 15.93% | 359,810 | 322.75K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 11.08% | 250,153 | 224.39K | Sep 29, 2024 |
| Whitefort Capital Management, LP | 3.63% | 81,902 | 73.47K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 1.85% | 41,839 | 37.53K | Sep 29, 2024 |
| HRT Financial LP | 1.51% | 34,030 | 30.52K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.22% | 5,077 | 4.55K | Oct 30, 2024 |
